CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
375 mg/m2 RRituximabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00379587
NCT00379587Phase 2Completed
CompareCT.gov

A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation

Dana-Farber Cancer Institute·interventional·Posted Sep 22, 2006·Updated Mar 19, 2014

In Brief

A Phase 2 clinical trial evaluating Rituximab and 375 mg/m2 RRituximab for Hematological Malignancies. Completed, enrolled 65 participants across 1 site.

Detailed Summary

The purpose of this trial is to determine if administration of rituximab after allogeneic stem cell transplantation can reduce the incidence of chronic GVHD. Chronic GVHD is a medical condition that can occur after bone marrow or stem cells are transplanted form one individual to another. After the transplant, the donor immune system may recognize the recipient body as foreign and may attempt to "reject" the body. Rituximab is a drug that interferes with the immune system function by specifically targeting B cells and killing them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Malignancies
CountriesUnited States
CollaboratorsGenentech, Inc., Biogen

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 22, 2006
Enrollment StartSep 1, 2006
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 19.8 years ago

Interventions

Rituximabdrug

Rituximab at months 3, 6, 9 and 12 post-transplant

375 mg/m2 RRituximabdrug

Rituximab 375 mg/m2 q3months